| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 2863718 | The American Journal of the Medical Sciences | 2011 | 9 Pages |
Abstract
Examination and reanalysis of unpublished data regarding rofecoxib has failed to confirm a safety advantage of rofecoxib over traditional nonsteroidal anti-inflammatory drugs in terms of complicated upper or lower GI events.
Related Topics
Health Sciences
Medicine and Dentistry
Cardiology and Cardiovascular Medicine
Authors
David Y. MD, Nicholas P. PhD, Francis K.L. MD,